The downgrade from Buy to Hold suggests that Deutsche Bank sees limited upside potential for Amedisys in the near term. Maintaining the price target at $101 indicates that the analyst does not expect significant price movement. This could lead to a short-term negative impact on the stock price as investors may adjust their expectations.